The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.01
Ask: 2.50
Change: 0.00 (0.00%)
Spread: 0.49 (24.378%)
Open: 2.15
High: 0.00
Low: 0.00
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Secretary Change

7 Oct 2022 16:44

RNS Number : 2369C
Immupharma PLC
07 October 2022
 

07 October 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Appointment of Company Secretary

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ward Williams Limited as Company Secretary to the Company. The appointment is with immediate effect.

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

 

 

+44 (0) 203 368 3550

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Ward Williams LimitedWard Williams is a leading provider of quality business support and personal financial services. They differentiate themselves through the range of services provided. Their client-focused services are delivered through two divisions: Chartered Accountants and HR Consultants, all working together from four locations in Weybridge, Uxbridge, Sunninghill and London. For more information go to: https://www.wardwilliams.co.uk/about-us/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
COSUPGGCUUPPGAM
Date   Source Headline
30th Apr 20207:00 amRNSFINAL RESULTS FOR THE 12M ENDED 31/12/19
6th Apr 20207:00 amRNSIMM live on Investor Meet Company platform 7 April
3rd Apr 20203:55 pmRNSHolding(s) in Company
2nd Apr 20208:26 amRNSHolding(s) in Company
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
30th Mar 20208:02 amRNS£1.5m Subscrip'n to fund R&D pipeline- replacement
30th Mar 20207:00 amRNS£1.5m Subscription to fund R&D pipeline expansion
20th Mar 20204:45 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension
4th Mar 20204:35 pmRNSPrice Monitoring Extension
28th Feb 20207:03 amRNSIncanthera plc – Admission to trading on NEX
21st Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20208:00 amRNSIncanthera announces Rule 23 Notice re NEX listing
12th Feb 20204:41 pmRNSSecond Price Monitoring Extn
12th Feb 20204:35 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSUpdate on the Avion Agreement
5th Feb 20204:40 pmRNSSecond Price Monitoring Extn
5th Feb 20204:35 pmRNSPrice Monitoring Extension
7th Jan 20204:40 pmRNSSecond Price Monitoring Extn
7th Jan 20204:35 pmRNSPrice Monitoring Extension
19th Dec 20194:35 pmRNSPrice Monitoring Extension
19th Dec 20197:00 amRNSAdmission today to trading on Euronext Growth
17th Dec 20197:00 amRNSPublication of Information Note (Euronext Growth)
13th Dec 20197:00 amRNSDual Listing on Euronext Growth Brussels
11th Dec 201912:49 pmRNSShare Price Volatility
3rd Dec 20197:00 amRNSIMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
2nd Dec 20197:00 amRNSTR-1: notification of major holdings
28th Nov 20197:00 amRNSLicence Agreement for Lupuzor with Avion in US
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
5th Nov 20194:41 pmRNSSecond Price Monitoring Extn
5th Nov 20194:35 pmRNSPrice Monitoring Extension
7th Oct 201912:07 pmRNSSecond Price Monitoring Extn
7th Oct 201912:02 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20197:00 amRNSInterim Results Announcement
18th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Jul 20197:00 amRNSTR-1: notification of major holdings
2nd Jul 20193:33 pmRNSTR-1: notification of major holdings
28th Jun 20197:00 amRNSUpdate on Lupuzor
27th Jun 20191:38 pmRNS2019 Annual General Meeting
26th Jun 20197:00 amRNSSubscription to raise £2.66 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.